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Abstract: Gene transfer vectors derived from gamma-retroviruses or lentiviruses are 
currently used for the gene therapy of genetic or acquired diseases. Retroviral vectors 
display a non-random integration pattern in the human genome, targeting either regulatory 
regions (gamma-retroviruses) or the transcribed portion of expressed genes (lentiviruses), 
and have the potential to deregulate gene expression at the transcriptional or  
post-transcriptional level. A recently developed alternative vector system derives from the 
avian sarcoma-leukosis alpha-retrovirus (ASLV) and shows favorable safety features 
compared to both gamma-retroviral and lentiviral vectors in preclinical models. We 
performed a high-throughput analysis of the integration pattern of self-inactivating (SIN) 
alpha-retroviral vectors in human CD34+ hematopoietic stem/progenitor cells (HSPCs) and 
compared it to previously reported gamma-retroviral and lentiviral vectors integration 
profiles obtained in the same experimental setting. Compared to gamma-retroviral and 
lentiviral vectors, the SIN-ASLV vector maintains a preference for open chromatin 
regions, but shows no bias for transcriptional regulatory elements or transcription units, as 
defined by genomic annotations and epigenetic markers (H3K4me1 and H3K4me3 histone 
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modifications). Importantly, SIN-ASLV integrations do not cluster in hot spots and  
target potentially dangerous genomic loci, such as the EVI2A/B, RUNX1 and LMO2 
proto-oncogenes at a virtually random frequency. These characteristics predict a safer 
profile for ASLV-derived vectors for clinical applications. 




Transplantation of hematopoietic stem cells genetically modified by retroviral vectors has proven 
its clinical efficacy in a number of seminal clinical trials for the treatment of severe monogenic 
disorders [1–8]. However, some of these studies also showed the genotoxic risks associated with the 
insertion of foreign DNA in the human genome, which limit the clinical application of integrating 
vectors (reviewed in [9]). Several efforts have been made to improve the safety of retroviral vectors, 
leading to the design of safer constructs and the development of robust in vitro and in vivo genotoxic 
assays to predict the potential risk associated with their integration into the genome [10–12].  
High-definition mapping of integration sites of vectors derived from the Moloney murine leukemia 
virus (MLV) and human immunodeficiency virus (HIV) in murine and human cells revealed  
non-random profiles with a strong tendency to target active regulatory regions for MLV-derived 
gamma-retroviral vectors [13,14] and transcribed regions for HIV-derived lentiviral vectors [15,16]. 
These integration patterns explain the relatively high risk to deregulate gene expression at the 
transcriptional or post-transcriptional level observed in pre-clinical, as well as in clinical studies 
(reviewed in [9]). 
Small-scale surveys of integration sites of vectors derived from alpha-retroviruses, such as the avian 
sarcoma-leukosis virus (ASLV), in different cell types indicated a more random pattern compared to 
other retroviruses, with a slight preference for transcription units, but no apparent preference for 
promoters and transcription start sites (TSSs) [17–20]. This potentially more favorable integration 
profile prompted the development of a replication-deficient, self-inactivating (SIN) ASLV-derived 
vector capable of efficiently transducing murine and human cells [21]. This vector was able to sustain 
long-term transgene expression in murine and human hematopoietic progenitors at levels comparable 
to those obtained with SIN-MLV and SIN-HIV vectors and to correct the X-linked chronic 
granulomatous disease (X-CGD) phenotype in a mouse model of the disease [20,22]. 
We and others previously reported that MLV, SIN-MLV and SIN-HIV integrations are highly 
clustered in the human genome, with cell-specific patterns that correlate with the transcriptional 
program and the epigenetic landscape of each cell type [14–16,19,23–26]. In this study, we report a 
high-definition analysis of the integration patterns of SIN-MLV, SIN-ASLV and SIN-HIV vectors in 
human CD34+ hematopoietic stem/progenitor cells (HSPCs), which was carried out to evaluate their 
comparative genotoxic potential in a clinically relevant target cell. We show that the SIN-ASLV 
integration profile is close to random, with no preferential targeting of TSSs or transcribed genes 
compared to SIN-MLV and SIN-HIV. The SIN-ASLV vector does not target CpG islands, conserved 




non-coding regions (CNCs) or elements enriched in transcription factor binding sites (TFBS), is less 
frequently associated with epigenetically defined promoter and enhancer regions compared to  
SIN-MLV and is randomly associated with repetitive elements in the genome. Similarly, we observed 
no preference for transcribed regions compared to SIN-HIV. Heterochromatic regions are excluded by 
the integration pattern of all three vectors. Interestingly, the ASLV vector showed no apparent 
clustering in the genome and has no association with the typical integration hot spots observed for 
MLV- and HIV-based vectors. These results highlight a safer integration profile of alpha-retroviral 
vectors in human cells, supporting their development as a clinical gene transfer tool. 
2. Experimental 
2.1. Vectors and Cells 
Human CD34+ HSPCs were purified form umbilical cord blood, pre-stimulated for 48 h in serum-free 
Iscove’s modified Dulbecco medium supplemented with 20% Fetal Calf Serum (FCS), 20 ng/mL human 
thrombopoietin, 100 ng/mL Flt-3 ligand, 20 ng/mL interleukin-6 and 100 ng/mL stem cell factor, as 
previously described [23]. HSPCs were transduced with the SIN-ASLV vector, pAlpha.SIN.EFS.EGFP.WPRE 
(noTATA), expressing GFP under the control of the elongation factor 1α promoter, pseudotyped in  
an amphotropic envelope by three-plasmid transfection in 293T cells, as previously described [20]. 
Cells were infected by 3 rounds of spinoculation (1500 rpm for 45 min) in the presence of 4 μg/mL 
polybrene. Transduction efficiency was evaluated by cytofluorimetric analysis of GFP expression 48 h 
after infection. 
2.2. Amplification, Sequencing, and Analysis of Retroviral Integration Sites 
Genomic DNA was extracted from a pool of 3.5 × 106 CD34+/GFP+ cells enriched by  
fluorescence-activated cell sorting, after a brief period in culture to dilute unintegrated vectors.  
3'-LTR vector-genome junctions were amplified by LM-PCR adapted to the GS-FLX Genome 
Sequencer (Roche/454 Life Sciences) pyrosequencing platform, as previously described [14].  
Raw sequence reads were processed by an automated bioinformatic pipeline that eliminated small and 
redundant sequences [14] and mapped on the University of California at Santa Cruz (UCSC) hg19 
release of the human genome [14]. All UCSC RefSeq genes having their TSS at ±50 kb from an 
integration site were annotated as targets. Genomic features were annotated when their genomic 
coordinates overlapped for ≥1 nucleotide with a ±1 kb interval around each integration site. We used 
UCSC tracks for both CpG islands and conserved TFBSs, and the previously described genomic 
coordinates of 82,335 mammalian conserved non-coding sequences (CNCs) [27]. Raw sequences 
having a single or ambiguous match in the genome (the latter mapping in multiple genomic positions 
with a difference in the identity <2) were blasted on the UCSC RepeatMasker database. DNase I 
hypersensitive sites from publicly available data [28] were annotated when overlapping for at least 1 
bp with a ±1-kb interval around an integration. Repetitive elements were annotated when directly 
targeted by each integration site. Sequences having multiple matches were collapsed and counted as 
one when matching in the same genomic positions and were univocally associated with the single type 
of repetitive element they targeted. 




For the association of the integrations with epigenetically defined chromatin states, we used 
publicly available ChIP-Seq data (NIH Roadmap Epigenomics Mapping Consortium database) that we 
re-annotated in the UCSC hg19 release of the human genome. We analyzed the distribution of 
integration sites around histone modifications (H3K4me1, H3K4me3, H3K36me3, H3K27me3) using 
the seqMINER platform [29]. Previously generated SIN-MLV, SIN-HIV integrations and random 
control sequences datasets [14] were also re-annotated on the UCSC hg19 genome. For all pairwise 
comparisons, we applied a 2-sided Fisher’s exact test. The threshold for statistical significance was set 
at a p-value < 0.01. 
3. Results and Discussion 
3.1. SIN-ASLV Vectors Exhibit an Almost Random Integration Profile in the Genome of Human  
CD34+ HSPCs 
To generate a high-definition alpha-retroviral integration profile in human HSPCs, we transduced 
umbilical cord blood-derived CD34+ cells with a previously described SIN-ASLV vector carrying a 
GFP expression cassette under the control of the intron-less, 240-bp version of the elongation  
factor-1α (EFS) promoter [20]. Cells were transduced at 10% to 20% efficiency and were selected for 
GFP expression by cell sorting 10 days after infection, to dilute unintegrated vectors. Vector-genome 
junctions were amplified from genomic DNA by ligation-mediated (LM)-PCR and pyrosequenced, as 
previously described [14]. Raw sequences (available at GenBank with the accession number 
SRR1282019) were processed by a previously described bioinformatic pipeline [14] and mapped on 
the UCSC hg19 release of the human genome, to obtain 8250 unique insertion sites. Two datasets of 
SIN-MLV (13,097) and SIN-HIV (31,827) vector integrations, previously generated in human umbilical 
cord blood-derived CD34+ cells in comparable experimental conditions, and a set of in-silico generated 
normalized random sites (40,000) [14,26] were re-annotated on the hg19 genome and used for 
comparison. To identify differences in the integration preferences of SIN-ASLV compared to SIN-MLV 
and SIN-HIV in human HSPCs, we first analyzed the distribution of integration sites around RefSeq 
genes in the human genome: integration was annotated as TSS-proximal when occurring in an interval 
of ±2.5 kb from the TSS of any RefSeq gene, intragenic when occurring inside a RefSeq gene >2.5 kb 
from the TSS and intergenic in all other cases. 
The high-definition profile of SIN-ASLV integration showed only a modest preference for TSSs 
(6.97% of the integration sites were annotated as TSS-proximal) compared to SIN-HIV and random 
sites (3.45% and 3.16%, respectively), which was significantly lower than that observed for the  
SIN-MLV vector (23.38%, p < 0.01). Similarly, SIN-ASLV showed only a slight tendency to integrate 
into genes (49.48% vs. 40.58% of random sites), significantly lower than that observed for SIN-HIV 
vectors (76.77%, p < 0.01). As a consequence, the frequency of SIN-ASLV integration outside 
transcription units was only slightly lower than random (43.55% vs. 56.26%) and significantly higher 
than those observed for the other two vectors (34.36% and 19.78%, respectively, p < 0.01) (Table 1). 
A plot of the relative distance of SIN-ASLV integration sites in an interval of ±50 kb from any TSS 
revealed a spread distribution with only a modest accumulation in the ±2.5 kb interval around TSS 
compared to the SIN-MLV vector. A higher definition map (100-bp intervals) showed the absence of 




integrations in the basal promoter region, most likely occupied by the RNA PolII basal transcriptional 
machinery. Integrations of the SIN-HIV vector were under-represented in a much wider interval of 
±2.5-kb around the TSS (Figure 1). 
Table 1. Integration distribution around RefSeq genes and genomic features in the genome 
















SIN-ASLV 43.55 * 6.97 49.48 2.84 5.49 55.70 8250 
SIN-MLV 34.36 * 23.38 * 42.26 17.68 * 8.42 69.95 * 13,097 
SIN-HIV 19.78 * 3.45 76.77 * 1.23 4.58 54.61 31,827 
Random 56.26 3.16 40.58 1.76 6.05 51.01 40,000 
Percentage of self-inactivating (SIN)-Moloney murine leukemia virus (MLV), SIN-avian sarcoma-leukosis 
alpha-retrovirus (ASLV) and SIN-HIV integrations and random sequences targeting intergenic, transcription 
start sites (TSS)-proximal and intragenic regions, regions annotated as CpG islands, conserved non-coding 
(CNC) regions and transcription factor binding sites (TFBS). For all the comparison with random sites, we 
applied a two-sided Fisher’s exact test. * p < 0.01. 
This analysis indicates that SIN-ASLV vector integrations have an almost random distribution in 
the human genome, with only a modest preference for genes and promoter regions compared to  
SIN-HIV and SIN-MLV vectors, suggesting entirely different modalities of target site selection. 
We previously reported that SIN-MLV integrations are enriched around annotated CpG islands and 
conserved TFBSs and moderately enriched around mammalian, evolutionarily conserved non-coding 
sequences (CNCs) [14,25,26]. SIN-ASLV integrations were found associated with these genomic 
features at almost a random frequency, as observed for SIN-HIV integrations, and at a much lower 
frequency compared to SIN-MLV integrations (CpGs: 2.84% vs. 17.68%; TFBSs: 55.70% vs. 69.95%; 
CNCs: 5.49% vs. 8.42%, p < 0.01 in all cases) (Table 1), suggesting again that SIN-ASLV integrations 
have no obvious association with functional genomic elements. 
We then looked at the tendency of the three types of retroviral vectors to target repetitive elements, 
by blasting both single- and multiple-match sequences to the UCSC RepeatMasker database and by 
annotating repetitive elements directly targeted by each integration site. Interestingly, only SIN-ASLV 
integrations were associated with repetitive elements with an almost random frequency (51% vs. 50%), 
while both SIN-MLV and SIN-HIV integrations were significantly under-represented in repetitive 
regions (37% and 45%, respectively, p < 0.01) (Table 2). By looking at the different classes of 
repetitive elements, we found that all three vectors have a slightly higher preference to integrate in 
short interspersed nuclear elements (SINEs) compared to random controls (17% to 20% vs. 15%), 
probably as a consequence of the fact that SINEs are often located in transcribed regions and contain 
PolII promoters [30,31]. On the contrary, integrations in long interspersed nuclear elements (LINEs), 
long terminal repeats (LTRs) and other repetitive elements were under-represented or close to random 
(Table 2). Finally, integration in satellite elements was observed at a random frequency only for  
SIN-ASLV vectors (0.43% vs. 0.35%), while both SIN-MLV and SIN-HIV integrations were significantly 
under-represented in these regions (0.01% and 0.05%, respectively, p < 0.01) (Table 2). 




Figure 1. Genomic distribution of SIN-MLV, SIN-ASLV and SIN-HIV integrations in 
human HSPCs. The distribution of the distance of SIN-MLV (red bars), SIN-ASLV 
(yellow bars) and SIN-HIV (blue bars) integration sites from the TSS of targeted genes at 
2500-bp (a) or 50-bp (b) resolution. The percentage of genes targeted at each position is 
plotted on the y-axis. The black line indicates the distribution of random control sites. 
 














SIN-ASLV (8,899) 51.29 19.50 19.77 0.43 6.26 5.35 
SIN-MLV (13,606) 37.75 10.96 17.26 0.01 5.09 4.42 
SIN-HIV (32,964) 45.78 19.45 16.86 0.05 4.08 5.35 
Random (40,000) 50.96 21.27 14.69 0.35 9.57 5.10 
Percentage of SIN-MLV, SIN-ASLV, SIN-HIV integrations and random sequences targeting repetitive 
elements and the percentage targeting each specific element: LINEs, short interspersed nuclear elements 
(SINEs), satellites, LTRs and all the other elements. 




Overall, these data indicate a remarkably random pattern of integration for the ASLV-derived 
vector, which shows none of the characteristic preferences of gamma-retroviruses and lentiviruses for 
genes and genetic elements associated with gene function and regulation. 
3.2. SIN-ASLV Integration Is Not Associated with Epigenetically-Defined Functional Genomic Regions 
Many studies have reported a strong correlation between MLV and HIV integration sites and 
distinct epigenetic markers in different cell types (reviewed in [9]). In human CD34+ HSPCs, MLV 
integrations are strongly associated with histone modifications marking transcriptionally active PolII 
promoters and enhancers, while HIV integrations correlate with epigenetic markers of active PolII 
elongation within transcription units [14,32]. We therefore investigated the association of SIN-ASLV 
integrations with defined epigenetic markers of functional genomic elements. Taking advantage of 
publicly available ChIP-Seq data in the genome of human CD34+ HSPCs, we analyzed the association 
of SIN-MLV, SIN-ASLV and SIN-HIV integrations with specific histone modifications defining 
active or poised PolII promoters, enhancers, transcribed regions and heterochromatin (H3K4me1, 
H3K4me3, H3K36me3, H3K27me3 and H3K27ac). 
More than 60% and 70% of SIN-MLV and SIN-HIV integrations sites, respectively, were 
univocally associated with a defined chromatin state, compared to only 40% of the SIN-ASLV 
integration sites, a frequency very close to the 30% observed for random sequences. In particular,  
SIN-ASLV integrations were found around regulatory regions, i.e., enhancer (H3K4me1+) and 
promoters (H3K4me3+), at a much lower frequency compared to SIN-MLV (10% vs. 37% in 
enhancers and 6% vs. 26% in promoters, respectively, p < 0.01), a tendency comparable to that 
observed for SIN-HIV (10% in enhancers and 4% in promoters) and slightly higher than that of the 
random sample (3% and 2%, respectively). Moreover, SIN-ASLV integrations were poorly associated 
with a marker of transcribed gene bodies (H3K36me3) compared to SIN-HIV (15% vs. 38%, p < 0.01). 
All three vectors were under-represented in heterochromatic regions marked by H3K27me3 compared 
to random sites, with the SIN-ASLV vector showing the highest association (Figure 2A). This analysis 
is in agreement with the associations observed at the level of DNA sequence and genomic annotations, 
and confirms the preference of SIN-MLV and SIN-HIV vectors for, respectively, regulatory sequences 
and transcribed regions and an almost random integration pattern for SIN-ASLV. The modest bias 
observed for SIN-ASLV integrations in DNase I hypersensitive regions compared to the random 
sample (Table S1) can be explained by a certain tendency to integrate in “open” chromatin regions, as 
observed for most retroviruses [14,16,33,34]. 
The differences between SIN-ASLV and the other two vectors in targeting defined chromatin 
regions are highlighted by plotting the average integration densities of each vector type around each 
histone modification. Indeed, we clearly observe a peak of SIN-MLV integration sites in a ±2.5-kb 
interval from epigenetically-defined enhancers and promoters, while the distribution of the SIN-ASLV 
and SIN-HIV integrations around these elements is similar to that observed for random sequences 
(Figure 2B). The quasi-random association of ASLV integrations in regulatory element predicts a 
much lower genotoxic risk compared to MLV-derived vectors, whose tendency to target active 
regulatory elements is at the basis of their propensity to cause insertional deregulation of gene 
expression [9]. Most (>70%) of the genes targeted by all three vectors in HSPCs are actively expressed 




(Figure S1), an expected finding, considering that retroviral target site selection is highly favored  
by an open chromatin state [14,16,33,34]. However, the SIN-ASLV vector targets the transcribed 
portion of active genes at a much lower frequency compared to HIV and is devoid of splicing signals, 
thus predicting a much lower risk to interfere with gene regulation at the post-transcriptional  
level [22,35,36]. 
Figure 2. Association of vector integration sites with different epigenetically-defined 
chromatin states. (a) The percentage of integration sites associated with specific, 
epigenetically defined genomic regions for each vector type. Chromatin states are 
categorized on the basis of the combination of different epigenetic marks mapped by  
ChIP-seq in human HSPCs. Only integration sites that are unambiguously associated with 
one chromatin state were used for the analysis. (b) The mean densities of H3K4me1, 
H3K4me3, H3K36me3 and H3K27me3 ChIP-seq fragments in a 5-kb window around all 
SIN-MLV (red), SIN-ASLV (yellow) and SIN-HIV (light blue) integration sites and 
random sequences (black). ac: H3K27ac. 
 
 




3.3. SIN-ASLV Vector Integrations Are Not Clustered in the Human Genome 
The integration profile of MLV- and HIV-derived vectors in the human genome is characterized by 
heavy clustering into integration hot spots, where MLV forms narrow clusters overlapping active 
regulatory elements and HIV larger clusters targeting a subset of transcribed genes, in both cases in a  
cell-specific fashion [14–16,24,37]. On the contrary, the SIN-ASLV vector showed no significant 
clustering when we applied a statistical definition of clusters adjusted to the numerosity of the sample [14], 
which for the SIN-ASLV dataset was three integrations in 53,920 bp. By this threshold, we were able 
to identify only 484 clusters, a significantly lower frequency compared to the 1,415 and 2,724 
identified for the SIN-MLV and SIN-HIV vectors, respectively (p < 0.01). Only 21% of all SIN-ASLV 
integrations are clustered, compared to 56% and 51% of SIN-MLV and SIN-HIV integrations, 
respectively (p < 0.01) (Table 3). Moreover, SIN-ASLV clusters are mostly made of few (three or 
four) integrations with few clusters containing up to nine integrations, while SIN-MLV and SIN-HIV 
clusters contain up to 37 and 122 integrations, respectively. From these data, it appears that, contrary 
to other retroviral vectors, SIN-ASLV integrations do not form hot spots of integrations in the human 
genome. Interestingly, when we looked at integration clusters at single genomic loci, we observed that 
the frequency of SIN-ASLV integrations at the typical MLV or HIV hot spots is very low and 
comparable to the frequency observed for random sequences. Figure 3 shows a comparison of the 
integration pattern of the three vectors in the NF1-EVI2A/B, RUNX1, LMO2 and PACS1 loci, four 
known hot spots for MLV or HIV integration. The same scenario is true for the EVI1/MDS1 
(MECOM) locus and all other MLV or HIV integration hot spots (data not shown). The low frequency 
of SIN-ASLV integration in proto-oncogenes responsible for the severe adverse events observed in 
clinical gene therapy trials, such as LMO2, provide a further indication of its lower genotoxic profile. 
Table 3. Clusters of integration sites in the genome of human HSPCs. 
 SIN-MLV (13,097) SIN-ASLV (8250) SIN-HIV (31,827) 
Clusters  1415 484 2724 
Integrations in clusters (%) 56 21 51 
Average cluster dimension 5.1 3.6 5.9 
The number of SIN-MLV, SIN-ASLV and SIN-HIV clusters of integrations, the percentage of integrations in 
clusters and the average cluster dimension, calculated based on random sequences distribution in the genome. 
The threshold for cluster definition was defined at a p-value of <0.01 by a statistical algorithm that adjusts for 
the numerosity of the sample [14]. 
Although the SIN-ASLV integration profile shows none of the features typical of MLV- and  
HIV-derived vectors, it is not completely random and shows a general preference for euchromatic 
regions. It is now know that both MLV and HIV pre-integration complexes (PICs) are targeted to 
chromatin by a tethering mechanism involving the interaction of the viral integrase with host cell factors: 
the LEDGF/p75 chromatin component interacts with the HIV integrase and directs its integration into 
transcribed gene bodies [38,39], while the MLV integrase appears to bind to bromodomain-containing 
BET proteins specifically associated with acetylated histones around TSSs and active regulatory  
elements [40–42]. Although it is likely that ASLV also may adopt a tethering mechanism to direct its 
integration in favorable genomic regions, the details are unknown. The integration preferences 




uncovered by our analysis predict an interaction with a broader range of host cell factors, which tether 
the PICs to open chromatin regions with unspecified or very subtle functional characteristics, thus 
leading to a more random profile characterized by the absence of hot spots. 
Figure 3. SIN-MLV, SIN-ASLV and SIN-HIV integration sites and clusters in  
CD34+ HSPC-specific loci. Distribution of SIN-MLV (red), SIN-ASLV (green) and  
SIN-HIV (blue) integration clusters (horizontal solid bars) and integrations (vertical marks) 
in the NF1-EVI2A/B, RUNX1, LMO2 and PACS1 loci, as displayed by the UCSC 
Genome Browser. 
 





Overcoming the genotoxic consequences of retroviral vector integration in the host cell genome is 
one of the major issues for the application of retroviral-based gene transfer in clinical trials. The strong 
preference to target TSSs, active regulatory elements or transcribed genes, together with the high 
frequency of clustering around hot spots, is a characteristics shared by all retroviral vectors currently 
used in clinical gene therapy. These characteristics are at the basis of the potential of retroviral 
insertion to deregulate gene expression at the transcriptional or post-transcriptional level, which has 
been observed to cause clonal expansion and contribute to neoplastic transformation in a number of 
cases (reviewed by [9]). Many efforts are being made to improve the safety of currently available 
retroviral vectors by removing the viral transcriptional control element and avoiding dominant,  
long-range acting enhancers in the transgene expression cassette. Retargeting vector integration has 
proven more difficult and was so far unsuccessful. No strategy is obviously perfect, and even a 
completely random integration machinery would not abolish the risk of inducing an insertional 
oncogenic mutation in the host cell genome. 
Based on a genome-wide analysis of >8000 integration sites in human HSPCs, we show that a  
SIN-ASLV vector has a quasi-random integration pattern that privileges active chromatin regions, but 
is not associated with active regulatory elements, like MLV, or with transcribed genes, like HIV. More 
importantly, the SIN-ASLV vector showed no integration hot spots and no preferences for subsets of 
genes with a defined ontology or genes that were previously identified as being activated by retroviral 
insertion into tumors. Previous evaluations of ASLV-derived vectors in pre-clinical models proved its 
ability to sustain long-term transgene expression in murine and human hematopoietic progenitors and 
to correct the pathology in a mouse model of X-linked Chronic Granulomatous Disease (X-CGD),  
with no evidence of post-transcriptional interference [20,22]. Combined with the use of short-range or 
cell-specific transcriptional regulatory elements, an ASLV vector appears to offer a very safe profile 
and to be an ideal candidate for ex vivo gene therapy applications. 
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